Abstract C234: Regulated immunomodulators expression using the RheoSwitch Therapeutic System® platform in human mesenchymal stem cells

• Published in: Molecular cancer therapeutics 2013-11, Vol.12 (11_Supplement), p.C234-C234
• Main Authors: Chan, Tim, Prabhu, Anjali, Elayadi, Anissa, Williams, Lindsay, Dailey, Vernon, Elliot, Kristi, Snipas, Tracey, Carson, Jonathan, Lewis, Jonathan, Schauer, Stephen, Bednarik, Daniel, Rieger, Jayson M., Humeau, Laurent M., Reed, Thomas R.
• Format: Article
• Language: English
• ISSN: 1535-7163; 1538-8514
• DOI: 10.1158/1535-7163.TARG-13-C234

The localization capability of human mesenchymal stem cell (hMSCs) to tumors offers an attractive possibility as a cellular vehicle delivery route of immunotherapeutic genes. The RheoSwitch Therapeutic System® (RTS®) platform allows for regulated expression following exposure and withdrawal of activator ligand (AL) veledimex (also known as INXN-1001). In this study, we first evaluated RTS® regulated IL-12 expression from adenovirally transduced hMSC to generate a genetically modified hMSC (GM-hMSC) that could be used as a vehicle for gene delivery with the added benefit of migration potential to the tumor for therapy. Following establishment of the cultures in vitro, hMSCs were phentoypically similar following adenoviral vector transduction to mock transduced hMSCs based upon marker expression, characterized by flow cytometry. Levels of human and mouse IL-12 secreted from the hMSCs transduced with Ad-RTS-hIL-12 and Ad-RTS-mIL-12 respectively, directly correlated with the viral vector doses (1K-20K vp/cell). hMSC transduction efficiency was ∼90% with an MOI of 20K/cell. In addition, sustained cell levels of IL-12 expression were observed up to 53 days following transduction when maintained in the presence of veledimex. Furthermore, cycling of in vitro exposure periods between veledimex and excipient demonstrated the ability for on/off/on and off/on/off kinetics of IL-12 expression by transduced hMSCs. We then expanded on the concept of RTS® regulated gene expression in GM-hMSCs using multigenic plasmid constructs that simultaneously expressed three immunomodulators - human IL-12, human IFNα, and a CTLA4 decoy - in single, dual or triple combinations. Transient transfection of the multieffector plasmid using the AMAXA nucleofector system resulted in RTS® regulated concomitant expression of all three effectors. hIL-12 and hIFNα were found to be fully bio-functional in their respective cell based functional assays; - hIL-12 increased IFNγ secretion from NK92 cells, hIFNα enhanced STAT1 reporter activity, and the CTLA4 decoy functional assay is in progress. Taken together, these in vitro studies highlight the potential use of MSCs for tumor-targeted delivery of single or multiple RTS® regulated cancer immunotherapies. Altogether, use of these novel regulated immunotherapeutic approaches could potentially be translated into an effective clinical regimen for a variety of cancers. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):C234. Citation Format: Tim C